|
|
 |
| Epigenomics AG Receives Allowance for Key Technology Patent in Japan |
Thursday, 11.03.2010 |
|
Patent broadly covers HeavyMethyl, a core technology of Epigenomics’ molecular diagnostic products
Press release, Berlin, Germany, and Seattle, WA, USA, March 11, 2010 |
|
| Ad Hoc Announcement Pursuant to §15 WpHG (German Securities Trading Act) Epigenomics AG: PRESEPT Academic Research Study Meets Its Primary Objective |
Monday, 08.03.2010 |
|
|
|
| Epigenomics AG Introduces New Lung Cancer Test at German Cancer Congress |
Wednesday, 24.02.2010 |
|
New IVD test expected to be launched in Q2 2010
Test supports accurate diagnosis of lung cancer in suspicious cases
Conference presentations on scientific evidence and clinical utility
Press release, Berlin, Germany, and Seattle, WA, U.S.A., |
|
| Epigenomics AG: Blood Test for Colorectal Cancer Now Available Nationwide in Germany and Switzerland |
Tuesday, 23.02.2010 |
|
Colorectal cancer test Epi proColon now available nationwide in Germany and Switzerland four months after product launch
Epigenomics to present recent clinical data at 29th German Cancer Congress (Deutscher Krebskongress) in Berlin, Germany
Press release, Berlin, Germany, and Seattle, WA, U.S.A., |
|
| Epigenomics AG Reports Conclusions from PRESEPT Study Audit |
Thursday, 04.02.2010 |
|
- Differences in analytical instrument read-out requires verification and potential retesting of samples measured in laboratory with deviating results
- Top-line data expected still in Q1 2010
- No impact on commercial strategy expected
Press release, Berlin, Germany, and Seattle, WA, U.S.A. |
|
| Ad Hoc Announcement Pursuant to §15 WpHG (German Securities Trading Act) Epigenomics AG Releases Preliminary PRESEPT Study Data |
Friday, 15.01.2010 |
|
|
|
| Ad Hoc Announcement pursuant of §15 WpHG (German Securities Trading Act): Epigenomics AG: Licensing Partner Quest Diagnostics Introduces Colorectal Cancer Blood Test in the U.S. |
Monday, 11.01.2010 |
|
|
|
top of the page
|
